



EXTENDED SPECTRUM β -LACTAMASES (ESBL) PRODUCING ENTEROBACTERIACEAE – CHALLENGE IN THE MEDICINE PRACTICE

G. Lazarova, K. Rachkova, D. Rukanova, H. Djeneva, I. Dukova

Thracian university – Medical faculty, Department of Microbiology and Virology,
Stara Zagora, Bulgaria

ABSTRACT

The growing use of broad-spectrum cephalosporins in recent years resulted in the appearance of the ESBLs. The first extended β -lactamase, designated SHV-2, was reported in Germany in 1983. Since then more and more extended-spectrum β -lactamases have been detected across the world.

The ESBLs are capable of hydrolyzing broad-spectrum cephalosporins and are inhibited by clavulanate and tazobactam.

The purpose: to summarize the data on the detection, monitoring and epidemiology of ESBLs-producing *Enterobacteriaceae* in our hospital during 6 years period using phenotype methods.

Results: *E. coli* ESBLs positive – 4.8%; *K. pneumoniae* – 13.2%; *Proteus* spp. – 2.8% respectively.

Conclusions: *K. pneumoniae* is the most common ESBLs-producer, followed by *E. coli* and *Proteus* spp.

Key words: Antimicrobial resistance, beta-lactams, *K. pneumoniae*, *E. coli*, *Proteus* spp.

INTRODUCTION

The growing use of broad-spectrum cephalosporins in recent years resulted in the appearance of the ESBLs. Now there exist a wide variety of extended-spectrum β -lactamases across the world.

The ESBLs are capable of hydrolyzing broad-spectrum cephalosporins and are inhibited by clavulanate and tazobactam(3,4). ESBLs-producing *Enterobacteriaceae* represent a true challenge for the physicians and the microbiologists because of: the need of exact laboratory detection and interpretative reading of the antimicrobial susceptibility tests (AST); common therapeutic failures, and the limited choice of the available antibiotics(5,8).

THE AIM

Phenotype investigation on the spread of

ESBLs – producing *Enterobacteriaceae* from University hospital patients during a six years period (2001 – 2006).

MATERIALS AND METHODS

The investigation includes 35518 specimens and 2604 isolates *Enterobacteriaceae* : 1417 from urine, 235 from low respiratory tract, 875 from wounds and 77 from blood.

The phenotype detection of ESBL was done according to CLSI/NCCLS 2003 using Double-Disc Synergism Method-DDS with Amoxicillin/Clavulanic acid + Ceftazidime, Cefotaxime and Cefpodoxime and Confirmatory Test discs (CAZ, CAZ-CLA; CTX, CTX-CLA), BD BBL Sensi-Disc ESBL(7).



Figure 1 – Double-Disc Synergism Method – ESBL positive strain

Table 1 – Distribution of *Enterobacteriaceae* isolates among specimens

| Specimens Isolates | Urine | Sputum | Wound | Haemoculture | Total (No/%) |
|----------------------|------------------|----------------|-----------------|---------------|-----------------|
| <i>E. coli</i> | 1066 | 60 | 461 | 38 | 1625/62,4 |
| <i>K.pneumoniae</i> | 175 | 175 | 102 | 19 | 471/18,1 |
| <i>Proteus spp.</i> | 132 | 0 | 188 | 0 | 320/12,3 |
| <i>K. oxytoca</i> | 11 | 0 | 19 | 1 | 31/1,2 |
| <i>E. cloacae</i> | 13 | 0 | 69 | 13 | 95/3,6 |
| <i>E. aerogenes</i> | 14 | 0 | 36 | 2 | 52/2,0 |
| <i>S. marcescens</i> | 6 | 0 | 0 | 4 | 10/0,4 |
| Total (No/%) | 1417/54,4 | 235/9,0 | 875/33,6 | 77/3,0 | 2604/100 |

The most common isolate among *Enterobacteriaceae* is *E. coli* (62.4%), mostly

from urine, followed by *K. pneumoniae* (18.1%) mostly from urine and sputum.

Table 2. Relative rate of the ESBL-producing microorganisms toward all isolates

| Period Isolates | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | Total |
|----------------------------|------|------|------|------|------|------|-------|
| <i>E. coli</i> | 331 | 352 | 207 | 234 | 236 | 256 | 1616 |
| ESBL <i>E. coli</i> % | 0.9 | 2.5 | 9.7 | 11.1 | 3.4 | 4.4 | 4.8 |
| <i>K.pneumoniae</i> | 70 | 89 | 101 | 74 | 81 | 56 | 471 |
| ESBL <i>K.pneumoniae</i> % | 3.0 | 18.0 | 26.7 | 6.7 | 7.4 | 10.7 | 13.2 |
| <i>Proteus spp.</i> | 62 | 44 | 47 | 46 | 51 | 68 | 318 |
| ESBL <i>Proteus spp.</i> % | 0 | 0 | 6.4 | 0 | 0 | 8.8 | 2.8 |

The most common ESBLs produser is *K. pneumoniae* (13.2%) from all *K. pneumoniae* isolates, followed by *E. coli* (4.8%) from all

E. coli isolates and *Proteus* spp. (2.8%) from all *Proteae*.




Figure 2 *ESBL-producing Enterobacteriaceae according to the specimens*

The most common specimen with ESBLs positive isolates is the blood; from the other specimens (urine, sputum, wounds) the frequency varies from 5.8% to 7.0%.

CONCLUSIONS

K. pneumoniae is the most common ESBLs-producer (13.2%), folowed by *E. coli* (4.8%). We established increasing of ESBLs positive *Enterobacteriaceae* during the years, irrespective of the restrictive antimicrobial politics in the University hospital(1,2,6,9). This tendency implies measures to reduce the incidence of infections with ESBL producing *Enterobacteriaceae* based on:

- the improvement of the collaboration with clinicians
- the epidemiological control : isolation and precautions for patients with ESBLs
- monitoring of antibiotic use and hospital staff education

REFERENCES

1. Лазарова Г., Д. Руканова, К. Рачкова, Х. Дженева, Е. Стайкова. Антибактериална резистентност на Грам-отрицателни бактерии, изолирани от болни с хирургически инфекции. 2005. Национална конференция по антибактериална терапия на хирургическите инфекции, Плевен, Сборник с доклади под редакцията на проф. Дамянов, 58-64.
2. Сотирова П., Д. Руканова, И. Дукова, К. Рачкова, Г. Лазарова, Х. Дженева. Антибактериална резистентност и бета-лактамна активност на изолати от сем. *Enterobacteriaceae*. Юбилейна научна конференция "20 години ВМИ-Ст.Загора", Октомври 2002; Стара Загора.
3. Bradford, P.A. Extended-spectrum β -lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. *Clin Microbiol Rev*, 14,4:933-951,2001.
4. Bush, K., Jacoby, G.A., Medeiros, A.A., A Functional Classification Scheme for β -Lactamases and Its Correlation with Molecular Structure. *Antimicrob Agents Chemother*, 39,6:1211-1233, 1995.
5. Gniadkovski, M., Evolution and epidemiology of extended-spectrum β -lactamases (ESBL) and ESBL-producing microorganisms. *Clin Microbiol Infect*, 7,11:597-608,2001.
6. Ivanova, D., Petrov, M., Velinov, Ts., Buchvarova, A., Kantardjiev, T., Hadjieva, N., Comparative study on antimicrobial resistance from two independent surveys for 2000. *Infectology*, XL,1:15-18,2000.

7. National Committee for Clinical Laboratory Standards, Wayne, PA, 21, 1, 2001.
8. Payne, D.G., Metallo- β -lactamases-a new therapeutic challenge. *J Med Microbiol*, 39:93-99, 1993.
9. Rachkova K., P. Sotirova, G. Lazarova, D. Rukanova, I. Dukova, H. Djeneva. Resistance to beta-lactam antibiotics and spread of ESBLs in Enterobacteriaceae. X Congress of the Bulgarian microbiologist with international participation, Plovdiv, 2002; MM22, 140.